

RISANKIZUMAB (Skyrizi® ▼) for Crohn's disease

The Cheshire and Merseyside Area Prescribing Group recommends the prescribing of RISANKIZUMAB (Skyrizi® ▼), by specialists only, for previously treated moderately to severely active Crohn's disease in accordance with NICE TA888.

RED

[NICE technology appraisal \(TA\) 888](#) (17 May 2023) recommends risankizumab as an option for treating moderately to severely active Crohn's disease in people 16 years and over, only if:

- > the disease has not responded well enough or lost response to a previous biological treatment **or**
- > a previous biological treatment was not tolerated **or**
- > tumour necrosis factor (TNF)-alpha inhibitors are not suitable.

Risankizumab is only recommended if the company provides it according to the commercial arrangement.^[1]

Risankizumab is commissioned by integrated care boards (ICBs) for people aged 18 years and over and is commissioned by NHS England for people aged 16 to 17 years.

If people with the condition and their clinicians consider risankizumab to be one of a range of suitable treatments after discussing the advantages and disadvantages of all options, the least expensive should be chosen taking into account administration costs, dosage, price per dose and commercial arrangements.^[1]

Prescribing and monitoring should be retained by a specialist in the treatment of Crohn's disease.

Costing information

NICE expects the resource impact of implementing the recommendations in England will be less than £5 million per year (or approximately £8,800 per 100,000 population). This is because risankizumab is a further treatment option and the overall cost of treatment will be similar to current treatment options.^[2]

References

1. National Institute for Health and Care Excellence. Technology appraisal guidance 888; [Risankizumab for previously treated moderately to severely active Crohn's disease](#), 17 May 2023. Accessed 18 May 2023.
2. National Institute for Health and Care Excellence. Technology appraisal guidance 888; [Resource impact statement: Risankizumab for previously treated moderately to severely active Crohn's disease](#), 17 May 2023. Accessed 18 May 2023.

Note: Patients who are not eligible for treatment under this statement may be considered on an individual basis where their GP or consultant believes exceptional circumstances exist that warrant deviation from the rule of this policy. In this situation, follow locally defined processes.